Free Trial

Arcutis Biotherapeutics (ARQT) Competitors

Arcutis Biotherapeutics logo
$16.47 -0.64 (-3.74%)
Closing price 03/26/2025 04:00 PM Eastern
Extended Trading
$16.52 +0.05 (+0.30%)
As of 03/26/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ARQT vs. ROIV, RVMD, LNTH, LEGN, TGTX, BBIO, AXSM, TLX, BPMC, and GRFS

Should you be buying Arcutis Biotherapeutics stock or one of its competitors? The main competitors of Arcutis Biotherapeutics include Roivant Sciences (ROIV), Revolution Medicines (RVMD), Lantheus (LNTH), Legend Biotech (LEGN), TG Therapeutics (TGTX), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry.

Arcutis Biotherapeutics vs.

Arcutis Biotherapeutics (NASDAQ:ARQT) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

In the previous week, Roivant Sciences had 4 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 15 mentions for Roivant Sciences and 11 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.23 beat Roivant Sciences' score of 0.74 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcutis Biotherapeutics
5 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Roivant Sciences
8 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Arcutis Biotherapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.

Arcutis Biotherapeutics received 14 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 78.26% of users gave Roivant Sciences an outperform vote while only 66.67% of users gave Arcutis Biotherapeutics an outperform vote.

CompanyUnderperformOutperform
Arcutis BiotherapeuticsOutperform Votes
68
66.67%
Underperform Votes
34
33.33%
Roivant SciencesOutperform Votes
54
78.26%
Underperform Votes
15
21.74%

64.8% of Roivant Sciences shares are held by institutional investors. 9.5% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 7.9% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Roivant Sciences has lower revenue, but higher earnings than Arcutis Biotherapeutics. Roivant Sciences is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcutis Biotherapeutics$196.54M9.94-$262.14M-$1.16-14.20
Roivant Sciences$122.59M60.77$4.35B-$0.15-69.60

Roivant Sciences has a net margin of -119.54% compared to Arcutis Biotherapeutics' net margin of -140.97%. Roivant Sciences' return on equity of -14.05% beat Arcutis Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcutis Biotherapeutics-140.97% -119.11% -45.95%
Roivant Sciences -119.54%-14.05%-12.81%

Arcutis Biotherapeutics presently has a consensus target price of $18.80, indicating a potential upside of 14.15%. Roivant Sciences has a consensus target price of $17.10, indicating a potential upside of 63.79%. Given Roivant Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Roivant Sciences is more favorable than Arcutis Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcutis Biotherapeutics
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
Roivant Sciences
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.00

Summary

Roivant Sciences beats Arcutis Biotherapeutics on 12 of the 19 factors compared between the two stocks.

Remove Ads
Get Arcutis Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARQT vs. The Competition

MetricArcutis BiotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.95B$6.90B$5.63B$8.13B
Dividend YieldN/A2.73%4.55%4.00%
P/E Ratio-9.207.1524.5019.08
Price / Sales9.94226.93385.3094.71
Price / CashN/A65.6738.1634.64
Price / Book17.526.486.954.36
Net Income-$262.14M$142.41M$3.20B$247.23M
7 Day Performance-1.79%-2.88%-2.18%-0.32%
1 Month Performance28.67%-4.52%3.14%-3.60%
1 Year Performance71.74%-8.69%11.29%2.01%

Arcutis Biotherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARQT
Arcutis Biotherapeutics
2.5478 of 5 stars
$16.47
-3.7%
$18.80
+14.1%
+77.7%$1.95B$196.54M-9.20150Short Interest ↓
Positive News
ROIV
Roivant Sciences
2.3562 of 5 stars
$10.85
+1.8%
$18.08
+66.7%
+3.6%$7.74B$122.59M-72.33860Insider Trade
Positive News
RVMD
Revolution Medicines
4.1302 of 5 stars
$39.13
+0.0%
$66.31
+69.5%
+25.7%$7.27B$742,000.00-10.90250Positive News
LNTH
Lantheus
4.277 of 5 stars
$102.76
+1.6%
$132.86
+29.3%
+67.5%$7.04B$1.53B17.10700Analyst Revision
LEGN
Legend Biotech
2.9144 of 5 stars
$37.94
+2.0%
$79.17
+108.7%
-38.0%$6.93B$627.24M-39.941,800Short Interest ↓
Positive News
TGTX
TG Therapeutics
3.0477 of 5 stars
$41.06
+0.5%
$40.67
-1.0%
+164.2%$6.45B$329.00M-410.56290Positive News
BBIO
BridgeBio Pharma
4.6889 of 5 stars
$33.01
+0.1%
$51.55
+56.2%
+21.3%$6.28B$221.90M-11.58400Analyst Forecast
Positive News
AXSM
Axsome Therapeutics
4.8223 of 5 stars
$125.68
+3.1%
$167.36
+33.2%
+55.3%$6.13B$385.69M-20.98380Short Interest ↓
Positive News
TLX
Telix Pharmaceuticals Limited American Depositary Shares
N/A$17.60
+1.7%
$22.00
+25.0%
N/A$5.93B$783.21M0.00N/AGap Up
BPMC
Blueprint Medicines
2.7968 of 5 stars
$92.14
+2.9%
$125.70
+36.4%
+1.2%$5.89B$508.82M-85.31640Insider Trade
Positive News
GRFS
Grifols
3.9526 of 5 stars
$8.10
+1.5%
N/A+15.1%$5.57B$7.21B6.9226,300Short Interest ↓
Remove Ads

Related Companies and Tools


This page (NASDAQ:ARQT) was last updated on 3/27/2025 by MarketBeat.com Staff
From Our Partners